b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="In-Process" Owner="NLM">\n        <PMID Version="1">31549458</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>06</Month>\n            <Day>17</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1442-2042</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>27</Volume>\n                    <Issue>1</Issue>\n                    <PubDate>\n                        <Year>2020</Year>\n                        <Month>Jan</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>International journal of urology : official journal of the Japanese Urological Association</Title>\n                <ISOAbbreviation>Int. J. Urol.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Ureteric stents: Overview of current clinical applications and economic implications.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>7-15</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1111/iju.14119</ELocationID>\n            <Abstract>\n                <AbstractText>Ureteric stents are one of the most crucial tools used for various clinical conditions in the urological field. Placement of a ureteric stent, for short- or long-term use, remains one of the commonest urological interventional procedures. In the past few decades, ureteral stents have undergone notable technological advancements. However, an ideal stent without significant side-effects is yet to be engineered. Indwelling ureteric stents are often accompanied by physical distress to the patient and clinical complications, such as bacterial adhesion, encrustation, malpositioning, stent fracture and forgotten stent syndrome, that influence patients\' health-related quality of life. In the market, different stent types are available, designed to reduce infections, and improve patient symptoms and tolerance. In this review, we have emphasized the recent developments that have taken place in stent design, size, materials and coating. This overview looks at current practices and problems related to stents, along with clinical and economic considerations. Few trial studies have been enumerated in the context of utilization of a ureteral stent symptom questionnaire and various stent models to compare their effects in patients.</AbstractText>\n                <CopyrightInformation>\xc2\xa9 2019 The Japanese Urological Association.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Sali</LastName>\n                    <ForeName>Gaurav Mohan</ForeName>\n                    <Initials>GM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Urology, University Hospital of Wales, Cardiff, UK.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Joshi</LastName>\n                    <ForeName>Hrishikesh B</ForeName>\n                    <Initials>HB</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Urology, University Hospital of Wales, Cardiff, UK.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D016454">Review</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>09</Month>\n                <Day>23</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Australia</Country>\n            <MedlineTA>Int J Urol</MedlineTA>\n            <NlmUniqueID>9440237</NlmUniqueID>\n            <ISSNLinking>0919-8172</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <CommentsCorrectionsList>\n            <CommentsCorrections RefType="CommentIn">\n                <RefSource>Int J Urol. 2020 Jan;27(1):16</RefSource>\n                <PMID Version="1">31637784</PMID>\n            </CommentsCorrections>\n        </CommentsCorrectionsList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Ureteral Stent Symptom Questionnaire</Keyword>\n            <Keyword MajorTopicYN="N">complications</Keyword>\n            <Keyword MajorTopicYN="N">economic</Keyword>\n            <Keyword MajorTopicYN="N">morbidity</Keyword>\n            <Keyword MajorTopicYN="N">ureteric stents</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>07</Month>\n                <Day>20</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>09</Month>\n                <Day>01</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>9</Month>\n                <Day>25</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>9</Month>\n                <Day>25</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>9</Month>\n                <Day>25</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31549458</ArticleId>\n            <ArticleId IdType="doi">10.1111/iju.14119</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Title>References</Title>\n            <Reference>\n                <Citation>Nabi G, Cook J, N\'Dow J, McClinton S. Outcomes of stenting after uncomplicated ureteroscopy: systematic review and meta-analysis. BMJ 2007; 334: 572.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Tolley D. Ureteric stents, far from ideal. Lancet 2000; 356: 872-3.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Zaki MR, Salman A, Chaudhary AH, Asif K, Rehman MU. Is DJ stenting still needed after uncomplicated ureteroscopic lithotripsy? A randomized controlled trial. Pak. J. Med. Health Sci. 2011; 5: 121-4.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Auge BK, Sarvis JA, L\'Esperance JO, Preminger GM. Practice patterns of ureteral stenting after routine ureteroscopic stone surgery: a survey of practicing urologists. J. Endourol. 2007; 21: 1287-91.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Bach P, Reicherz A, Teichman J et\xc2\xa0al. Short-term external ureter stenting shows significant benefit in comparison to routine double-J stent placement after ureterorenoscopic stone extraction: a prospective randomized trial - the Fast track stent study (FaST). Int. J. Urol. 2018; 25: 717-22.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Tavakoli A, Surange RS, Pearson RC, Parrott NR, Augustine T, Riad HN. Impact of stents on urological complications and health care expenditure in renal transplant recipients: results of a prospective, randomized clinical trial. J. Urol. 2007; 177: 2260-4.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Dauw CA, Simeon L, Alruwaily AF et\xc2\xa0al. Contemporary practice patterns of flexible ureteroscopy for treating renal stones: results of a worldwide survey. J. Endourol. 2015; 29: 1221-30.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Wang H, Man L, Li G, Huang G, Liu N, Wang J. Meta-analysis of stenting versus non-stenting for the treatment of ureteral stones. PLoS One 2017; 12: e0167670-e.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Ordonez M, Hwang EC, Borofsky M, Bakker CJ, Gandhi S, Dahm P. Ureteral stent versus no ureteral stent for ureteroscopy in the management of renal and ureteral calculi. Cochrane Database of Syst. Rev. 2019; CD012703.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Joshi H. Re: ureteral stent encrustation, incrustation, and coloring: morbidity related to indwelling times. J. Endourol. 2012; 26: 924-5.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Canales BK, Higgins L, Markowski T, Anderson L, Li QA, Monga M. Presence of five conditioning film proteins are highly associated with early stent encrustation. J. Endourol. 2009; 23: 1437-42.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Vanderbrink BA, Rastinehad AR, Ost MC, Smith AD. Encrusted urinary stents: evaluation and endourologic management. J. Endourol. 2008; 22: 905-12.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Lange D, Bidnur S, Hoag N, Chew BH. Ureteral stent-associated complications-where we are and where we are going. Nat. Rev. Urol. 2015; 12: 17-25.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Kawahara T, Ito H, Terao H, Yoshida M, Matsuzaki J. Ureteral stent encrustation, incrustation, and coloring: morbidity related to indwelling times. J. Endourol. 2012; 26: 178-82.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Acosta-Miranda AM, Milner J, Turk TM. The FECal Double-J: a simplified approach in the management of encrusted and retained ureteral stents. J. Endourol. 2009; 23: 409-15.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Chew BH, Lange D. Re: ureteral stent encrustation, incrustation, and coloring: morbidity related to indwelling times. J. Endourol. 2013; 27: 506.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Dyer RB, Chen MY, Zagoria RJ, Regan JD, Hood CG, Kavanagh PV. Complications of ureteral stent placement. Radiographics 2002; 22: 1005-22.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Kehinde EO, Rotimi VO, Al-Hunayan A, Abdul-Halim H, Boland F, Al-Awadi KA. Bacteriology of urinary tract infection associated with indwelling J ureteral stents. J. Endourol. 2004; 18: 891-6.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Kehinde EO, Rotimi VO, Al-Awadi KA et\xc2\xa0al. Factors predisposing to urinary tract infection after J ureteral stent insertion. J. Urol. 2002; 167: 1334-7.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Klis R, Korczak-Kozakiewicz E, Denys A, Sosnowski M, Rozanski W. Relationship between urinary tract infection and self-retaining Double-J catheter colonization. J. Endourol. 2009; 23: 1015-9.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Abdelaziz AY, Fouda WB, Mosharafa AA, Abelrasoul MA, Fayyad A, Fawzi K. Forgotten ureteral stents: risk factors, complications and management. Afr. J. Urol. 2018; 24: 28-33.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Tang VC, Gillooly J, Lee EW, Charig CR. Ureteric stent card register - a 5-year retrospective analysis. Ann. R. Coll. Surg. Engl. 2008; 90: 156-9.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Sancaktutar AA, Tepeler A, Soylemez H et\xc2\xa0al. A solution for medical and legal problems arising from forgotten ureteral stents: initial results from a reminder short message service (SMS). Urol. Res. 2012; 40: 253-8.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG. Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J. Urol. 2003; 169: 1060-4.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Lingeman JE, Preminger GM, Goldfischer ER, Krambeck AE. Assessing the impact of ureteral stent design on patient comfort. J. Urol. 2009; 181: 2581-7.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Joshi HB, Chitale SV, Nagarajan M et\xc2\xa0al. A prospective randomized single-blind comparison of ureteral stents composed of firm and soft polymer. J. Urol. 2005; 174: 2303-6.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Lennon GM, Thornhill JA, Sweeney PA, Grainger R, McDermott TE, Butler MR. \xe2\x80\x9cFirm\xe2\x80\x9d versus \xe2\x80\x9csoft\xe2\x80\x9d double pigtail ureteric stents: a randomised blind comparative trial. Eur. Urol. 1995; 28: 1-5.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Davenport K, Kumar V, Collins J, Melotti R, Timoney AG, Keeley FX Jr. New ureteral stent design does not improve patient quality of life: a randomized, controlled trial. J. Urol. 2011; 185: 175-8.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Lee C, Kuskowski M, Premoli J, Skemp N, Monga M. Randomized evaluation of ureteral stents using validated symptom questionnaire. J. Endourol. 2005; 19: 990-3.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Dunn MD, Portis AJ, Kahn SA et\xc2\xa0al. Clinical effectiveness of new stent design: randomized single-blind comparison of tail and double-pigtail stents. J. Endourol. 2000; 14: 195-202.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Ho CH, Chen SC, Chung SD et\xc2\xa0al. Determining the appropriate length of a double-pigtail ureteral stent by both stent configurations and related symptoms. J. Endourol. 2008; 22: 1427-31.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Al-Kandari AM, Al-Shaiji TF, Shaaban H, Ibrahim HM, Elshebiny YH, Shokeir AA. Effects of proximal and distal ends of double-J ureteral stent position on postprocedural symptoms and quality of life: a randomized clinical trial. J. Endourol. 2007; 21: 698-702.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Erturk E, Sessions A, Joseph JV. Impact of ureteral stent diameter on symptoms and tolerability. J. Endourol. 2003; 17: 59-62.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Al Aown A, Iason K, Panagiotis K, Liatsikos EN. Clinical experience with ureteral metal stents. Indian J. Urol. 2010; 26: 474-9.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>University Hospitals Cleveland Medical Center. The RELIEF\xe2\x84\xa2 Ureteral Stent - Assessment of Retrograde Urinary Reflux and Distal Coil Bladder Position. University Hospitals Cleveland Medical Center, Cleveland, 2017.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Rao MV, Polcari AJ, Turk TM. Updates on the use of ureteral stents: focus on the Resonance((R)) stent. Med. Devices 2011; 4: 11-5.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Chung KJ, Park BH, Park B et\xc2\xa0al. Efficacy and safety of a novel, double-layered, coated, self-expandable metallic mesh stent (Uventa) in malignant ureteral obstructions. J. Endourol. 2013; 27: 930-5.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Campschroer T, Lock MT, Lo RT, Bosch JL. The Wallstent: long-term follow-up of metal stent placement for the treatment of benign ureteroileal anastomotic strictures after Bricker urinary diversion. BJU Int. 2014; 114: 910-5.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Hendlin K, Dockendorf K, Horn C, Pshon N, Lund B, Monga M. Ureteral stents: coil strength and durometer. Urology 2006; 68: 42-5.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Davenport K, Kumar V, Collins J, Melotti R, Keeley FX, Timoney AG. Prospective randomized trial the Bard Inlay ureteric stent with the Boston Scientific Polaris stent using the validated ureteric stent symptom questionnaire. Eur. Urol. Suppl. 2008; 7: 107.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Park HK, Paick SH, Kim HG, Lho YS, Bae S. The impact of ureteral stent type on patient symptoms as determined by the ureteral stent symptom questionnaire: a prospective, randomized, controlled study. J. Endourol. 2015; 29: 367-71.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Candela JV, Bellman GC. Ureteral stents: impact of diameter and composition on patient symptoms. J. Endourol. 1997; 11: 45-7.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Mucksavage P, Pick D, Haydel D et\xc2\xa0al. An in vivo evaluation of a novel spiral cut flexible ureteral stent. Urology 2012; 79: 733-7.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Chew BH, Rebullar KA, Harriman D, McDougall E, Paterson RF, Lange D. Percuflex helical ureteral stents significantly reduce patient analgesic requirements compared to control stents. J. Endourol. 2017; 31: 1321-5.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Stoller ML, Schwartz BF, Frigstad JR, Norris L, Park JB, Magliochetti MJ. An in vitro assessment of the flow characteristics of spiral-ridged and smooth-walled JJ ureteric stents. BJU Int. 2000; 85: 628-31.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Olweny EO, Portis AJ, Sundaram CP et\xc2\xa0al. Evaluation of a chronic indwelling prototype mesh ureteral stent in a porcine model. Urology 2000; 56: 857-62.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Mosayyebi A, Manes C, Carugo D, Somani BK. Advances in ureteral stent design and materials. Curr. Urol. Rep. 2018; 19: 35.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Taylor WN, McDougall IT. Minimally invasive ureteral stent retrieval. J. Urol. 2002; 168: 2020-3.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Battaglia M, Ditonno P, Selvaggio O et\xc2\xa0al. Double J stent with antireflux device in the prevention of short-term urological complications after cadaveric kidney transplantation: single-center prospective randomized study. Transpl. Proc. 2005; 37: 2525-6.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Kim HH, Choi YH, Lee SB, Baba Y, Kim KW, Suh SH. Numerical analysis of urine flow through the side holes of a double J stent in a ureteral stenosis. Technol. Health Care 2017; 25: 63-72.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Chew BH, Paterson RF, Clinkscales KW, Levine BS, Shalaby SW, Lange D. In vivo evaluation of the third generation biodegradable stent: a novel approach to avoiding the forgotten stent syndrome. J. Urol. 2013; 189: 719-25.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Barros AA, Oliveira C, Ribeiro AJ et\xc2\xa0al. In vivo assessment of a novel biodegradable ureteral stent. World J. Urol. 2018; 36: 277-83.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Oliver R, Wells H, Traxer O et\xc2\xa0al. Ureteric stents on extraction strings: a systematic review of literature. Urolithiasis 2018; 46: 129-36.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Mosayyebi A, Vijayakumar A, Yue QY et\xc2\xa0al. Engineering solutions to ureteral stents: material, coating and design. Cent. Eur. J. Urol. 2017; 70: 270-4.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Erbel R, Di Mario C, Bartunek J et\xc2\xa0al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 2007; 369: 1869-75.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Krebs A, Deane LA, Borin JF et\xc2\xa0al. The \xe2\x80\x9cbuoy\xe2\x80\x9d stent: evaluation of a prototype indwelling ureteric stent in a porcine model. BJU Int. 2009; 104: 88-92.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Lange D, Hoag NA, Poh BK, Chew BH. Drainage characteristics of the 3F MicroStent using a novel film occlusion anchoring mechanism. J. Endourol. 2011; 25: 1051-6.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Ecke TH, Bartel P, Hallmann S, Ruttloff J. Evaluation of symptoms and patients\xe2\x80\x99 comfort for JJ-ureteral stents with and without antireflux-membrane valve. Urology 2010; 75: 212-6.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Norris RD, Sur RL, Springhart WP et\xc2\xa0al. A prospective, randomized, double-blinded placebo-controlled comparison of extended release oxybutynin versus phenazopyridine for the management of postoperative ureteral stent discomfort. Urology 2008; 71: 792-5.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Deliveliotis C, Chrisofos M, Gougousis E, Papatsoris A, Dellis A, Varkarakis IM. Is there a role for alpha1-blockers in treating double-J stent-related symptoms? Urology 2006; 67: 35-9.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Beddingfield R, Pedro RN, Hinck B, Kreidberg C, Feia K, Monga M. Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study. J. Urol. 2009; 181: 170-6.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Damiano R, Autorino R, De Sio M, Giacobbe A, Palumbo IM, D\'Armiento M. Effect of tamsulosin in preventing ureteral stent-related morbidity: a prospective study. J. Endourol. 2008; 22: 651-6.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Park SC, Jung SW, Lee JW, Rim JS. The effects of tolterodine extended release and alfuzosin for the treatment of double-j stent-related symptoms. J. Endourol. 2009; 23: 1913-7.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Dellis AE, Papatsoris AG, Keeley FX Jr, Bamias A, Deliveliotis C, Skolarikos AA. Tamsulosin, solifenacin, and their combination for the treatment of stent-related symptoms: a randomized controlled study. J. Endourol. 2017; 31: 100-9.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Tae BS, Cho S, Jeon BJ et\xc2\xa0al. Does mirabegron relieve ureteric stent-related discomfort? A prospective, randomized, multicentre study. BJU Int. 2018; 122: 866-72.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Tharwat M, Elsaadany MM, Lashin AM, El-Nahas AR. A randomized controlled trial evaluating sildenafil citrate in relieving ureteral stent-related symptoms. World J. Urol. 2018; 36: 1877-81.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Ragab M, Soliman MG, Tawfik A et\xc2\xa0al. The role of pregabalin in relieving ureteral stent-related symptoms: a randomized controlled clinical trial. Int. Urol. Nephrol. 2017; 49: 961-6.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Maldonado-Avila M, Garduno-Arteaga L, Jungfermann-Guzman R et\xc2\xa0al. Efficacy of tamsulosin, oxybutynin, and their combination in the control of double-J stent-related lower urinary tract symptoms. Int. Braz. J. Urol. 2016; 42: 487-93.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Liu S, Yu Y, Gao Y, Yang X, Pang Z. Decreased urinary glycosaminoglycan excretion following alfuzosin treatment on ureteral stent-related symptoms: a prospective, randomized, placebo-controlled study. Urolithiasis 2016; 44: 185-90.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Assimos D, Krambeck A, Miller NL et\xc2\xa0al. Surgical management of stones: American Urological Association/Endourological Society guideline. Part I. J. Urol. 2016; 196: 1153-60.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Gupta M, Patel T, Xavier K et\xc2\xa0al. Prospective randomized evaluation of periureteral botulinum toxin type A injection for ureteral stent pain reduction. J. Urol. 2010; 183: 598-602.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Tadros NN, Bland L, Legg E, Olyaei A, Conlin MJ. A single dose of a non-steroidal anti-inflammatory drug (NSAID) prevents severe pain after ureteric stent removal: a prospective, randomised, double-blind, placebo-controlled trial. BJU Int. 2013; 111: 101-5.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Wang CJ, Huang SW, Chang CH. Effects of specific alpha-1A/1D blocker on lower urinary tract symptoms due to double-J stent: a prospectively randomized study. Urol. Res. 2009; 37: 147-52.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Lee YJ, Huang KH, Yang HJ, Chang HC, Chen J, Yang TK. Solifenacin improves double-J stent-related symptoms in both genders following uncomplicated ureteroscopic lithotripsy. Urolithiasis 2013; 41: 247-52.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>El-Nahas AR, Tharwat M, Elsaadany M, Mosbah A, Gaballah MA. A randomized controlled trial comparing alpha blocker (tamsulosin) and anticholinergic (solifenacin) in treatment of ureteral stent-related symptoms. World J. Urol. 2016; 34: 963-8.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Wang J, Zhang X, Zhang T, Mu J, Bai B, Lei Y. The role of solifenacin, as monotherapy or combination with tamsulosin in ureteral stent-related symptoms: a systematic review and meta-analysis. World J. Urol. 2017; 35: 1669-80.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Zhang YM, Chu P, Wang WJ. PRISMA-combined alpha-blockers and antimuscarinics for ureteral stent-related symptoms: a meta-analysis. Medicine 2017; 96: e6098.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Desgrandchamps F, Moulinier F, Daudon M, Teillac P, Le Duc A. An in vitro comparison of urease-induced encrustation of JJ stents. Br. J. Urol. 1997; 79: 24-7.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Krambeck AE, Walsh RS, Denstedt JD et\xc2\xa0al. A novel drug eluting ureteral stent: a prospective, randomized, multicenter clinical trial to evaluate the safety and effectiveness of a ketorolac loaded ureteral stent. J. Urol. 2010; 183: 1037-42.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Khandwekar AP, Doble M. Physicochemical characterisation and biological evaluation of polyvinylpyrrolidone-iodine engineered polyurethane (Tecoflex((R))). J. Mater. Sci. - Mater. Med. 2011; 22: 1231-46.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Laube N, Kleinen L, Bradenahl J, Meissner A. Diamond-like carbon coatings on ureteral stents-a new strategy for decreasing the formation of crystalline bacterial biofilms? J. Urol. 2007; 177: 1923-7.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Watterson JD, Cadieux PA, Beiko DT et\xc2\xa0al. Oxalate-degrading enzymes from Oxalobacter formigenes: a novel device coating to reduce urinary tract biomaterial-related encrustation. J. Endourol. 2003; 17: 269-74.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Mendez-Probst CE, Goneau LW, MacDonald KW et\xc2\xa0al. The use of triclosan eluting stents effectively reduces ureteral stent symptoms: a prospective randomized trial. BJU Int. 2012; 110: 749-54.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Chew BH, Davoudi H, Li J, Denstedt JD. An in vivo porcine evaluation of the safety, bioavailability, and tissue penetration of a ketorolac drug-eluting ureteral stent designed to improve comfort. J. Endourol. 2010; 24: 1023-9.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Multanen M, Tammela TL, Laurila M et\xc2\xa0al. Biocompatibility, encrustation and biodegradation of ofloxacine and silver nitrate coated poly-L-lactic acid stents in rabbit urethra. Urol. Res. 2002; 30: 227-32.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Phuengkham H, Nasongkla N. Development of antibacterial coating on silicone surface via chlorhexidine-loaded nanospheres. J. Mater. Sci. Mater. Med. 2015; 26: 78.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Liatsikos EN, Karnabatidis D, Kagadis GC et\xc2\xa0al. Application of paclitaxel-eluting metal mesh stents within the pig ureter: an experimental study. Eur. Urol. 2007; 51: 217-23.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Kallidonis P, Kitrou P, Karnabatidis D et\xc2\xa0al. Evaluation of zotarolimus-eluting metal stent in animal ureters. J. Endourol. 2011; 25: 1661-7.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Dellis A, Joshi HB, Timoney AG, Keeley FX Jr. Relief of stent related symptoms: review of engineering and pharmacological solutions. J. Urol. 2010; 184: 1267-72.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Teichmann DA, Joshi HB. Indwelling ureteric stents - health economics considerations. In: Kulkarni R (ed). Ureteric Stenting. John Wiley &amp; Sons Ltd, Chichester, 2017; 287-95.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Lopez-Huertas HL, Polcari AJ, Acosta-Miranda A, Turk TM. Metallic ureteral stents: a cost-effective method of managing benign upper tract obstruction. J. Endourol. 2010; 24: 483-5.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Lynch MF, Ghani KR, Frost I, Anson KM. Preventing the forgotten ureteric stent: results from the implementation of an electronic stent register. BJU Int. 2007; 99: 245-6.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Staubli SEL, Mordasini L, Engeler DS, Sauter R, Schmid HP, Abt D. Economic aspects of morbidity caused by ureteral stents. Urol. Int. 2016; 97: 91-7.</Citation>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'